STING1 and breast neoplasm: Zhao and colleagues have uncovered a stimulator of interferon genes (STING)-dependent antitumor immune response (inducible by a STING agonist) that can reprogram the M2-like tumor associated macrophages (TAMs) predominant in breast tumor cells to the M1-like TAMs characteristic of ovarian tumors [152,153].